News FDA approves Pfizer's Besponsa in aggressive blood cancer Besponsa becomes first of its kind indicated for rare type of acute lymphoblastic leukaemia.
News The curious case of Mylotarg: Pfizer's leukaemia drug set to... Mylotarg backed by advisers after withdrawal in 2010.
News Novartis CAR-T safety in FDA spotlight FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to focus on safety concerns in the decisive meeting.
News Pfizer facing NICE showdown over leukaemia drug Pfizer locks horns with NICE following EU approval.
News NICE green light a win for Lilly in RA market RA drug backed after manufacturer offered discount.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.